Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
$6.23-0.03%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-48.6%
The outlook
Aardvark Therapeutics, Inc. currently reads as neutral based on buy — 2.3 avg of 10 analysts, mixed vs its moving averages, 20% of the way from its 52-week low to high, avg target +133% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Analyst consensusBuy — 2.3 avg of 10 analysts
Price trendMixed vs its moving averages
52-week range20% of the way from its 52-week low to high
Price targetAvg target +133% vs current price
Analyst price target
~12-month · 10 analysts$14.50average target+132.7% vs now
Now $6.23
Low $3.00High $45.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$136.3M
52-wk high
$17.94
52-wk low
$3.35
50-day avg
$4.97
200-day avg
$8.59
Trailing P/E
—